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Background
The exacerbation of malaria in sub-Saharan Africa
towards the end of the 20th century accrued from
amplified resistance to chloroquine and sulfadoxine-pyr-
imethamine (SP) the most affordable antimalaria medi-
cines [1]. Contact with substandard antimalarial
medicines probably aggravated this development [2-4].
Pressure from malaria scientists triggered extensive
acceptance and implementation of artemisinin-based
combination therapies (ACTs) by endemic country gov-
ernments and donors [5]. All medicines carry some risk
of harm and it is important to monitor their intended
and unwanted effects for good evidence upon which to
base an assessment of risk versus effectiveness or risk
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Table 1 Proportion of patients with suspected adverse drug reactions (SADRs) to various Artemisinin-based
combination therapies (ACT) in Lagos (2008).
SADRs Artemisinin
Monotherapy (number
of reports=410)
Artesunate-Mefloquine
(number of
reports=521)
Artesunate-
Amodiaquine (number
of reports=961)
Artemeter-
Lumefantrine (number
of reports=401)
Dihydro artemisinin/SP
(number of
reports=642)
Anorexia 19 25 52 14 33
Tightening
of chest
71 7 2 61 39
Rashes 10 21 28 20 55
Pruritis 6 22 39 16 28
Dizziness 33 48 93 32 39
Restlessness 35 35 79 24 29
Headache 39 31 51 25 37
General
body pain
19 24 43 16 18
Weakness/
fatigue
43 47 102 32 46
Vomiting 5 11 15 5 20
Abdominal
discomfort
37 25 52 30 32
Insomnia 17 21 46 13 29
Swollen/
blistered lips
9 6 10 11 46
Hallucination 3 17 16 9 14
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any medium, provided the original work is properly cited.versus benefit. Furthermore, particularly with new medi-
cines, the early identification of unexpected adverse
reactions and their risk factors is essential, so that the
medicines can be used in an informed manner with the
least chance of harm. This is the role of pharmacovigi-
lance (PV). Information gathered during pharmacovigi-
lance may also assist in selecting the most appropriate
medicine for future use. The objectives of this study
were to document the suspected undesirable but com-
mon adverse drug reactions (SADRs) of patients using
various Artemisinin-based Combination therapies
(ACTs) in Lagos, (Nigeria) and to document the invol-
vement of community pharmacists in the detection and
reporting of these ADRs.
Materials and methods
A semi-structured questionnaire was served to each of
the 235 randomly selected community pharmacists/
respondents in urban and semi-urban Lagos metropolis
between May and July 2008 out of which 201 (83.8%)
responded.
Results
Nine hundred and sixty one reports of SADR to Artesu-
nate-Amodiaquine (AA) combination were reported fol-
lowed by 642 to dihydro-artemisinin-SP combination,
521 to Artesunate-Mefloquine combination, 401 to
Artemisinin monotherapies and 401 to Artemeter-
Lumefantrin combination (Table 1). When Artesunate
Amodiaquine was compared with Artemeter Lumefan-
trin, there were significant differences in the proportion
of patients with weakness and fatigue (102, 37.8%; 32,
11.9%; OR 4.52; p<0.0001), dizziness (93, 38.0%; 32,
12.1%; OR 4.07; p<0.0001), headache (51, 27.9%; 25,
13.7%; OR 2.44; p<0.0001), insomnia (46, 36.5%; 13,
10.3%; OR 5.00; p<0.0001), abdominal discomfort (52,
28.5%; 30, 17.0%; OR 1.6; p<0.05) and depression (14,
44.1%; 3, 8.8%; OR 8.16; p<0.0001).
Conclusions
Suspected adverse drug reactions especially to AA are
factors that limit its use as an effective ACT which has
unpalatable reactions to the patient. The confidence of
end users of this particular ACT wanes with the devel-
opment of suspected but constant mild, moderate to
severe adverse drug reactions.
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